Receptor-dependent (RD) 3D-QSAR approach of a series of benzylpiperidine inhibitors of human acetylcholinesterase (HuAChE)

European Journal of Medicinal Chemistry

Volumn 46, Issue 1, 2011, Pages 39-51

  Araújo, Jocley Queiroz ^a   De Brito, Monique Araújo ^b   Hoelz, Lucas Villas Bôas ^a   De Alencastro, Ricardo Bicca ^a   Castro, Helena Carla ^b   Rodrigues, Carlos Rangel ^a   Albuquerque, Magaly Girão ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Acetylcholinesterase; Alzheimer disease; Benzylpiperidine; Molecular modeling; RD 3D QSAR

Indexed keywords

ACETYLCHOLINESTERASE; BENZYLPIPERIDINE DERIVATIVE; CHOLINESTERASE INHIBITOR; DONEPEZIL; UNCLASSIFIED DRUG;

ARTICLE; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; IC 50; LIGAND BINDING; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

EID: 78650512410     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2010.10.009     Document Type: Article

References (68)

1. M.D.M. Alcala, N.M. Vivas, S. Hospital, P. Camps, D. Munoz-Torrero, and A. Badia Characterisation of the anticholinesterase activity of two new tacrine-huperzine A hybrids Neuropharmacology 44 2003 749 755
2. N.R. Cutler, and J.J. Sramek Review of the next generation of Alzheimer's disease therapeutics: Challenges for drug development Prog. Neuro-Psychopharmacol. Biol. Psychiatry 25 2001 27 57
3. S.D. Ginsberg, S. Che, S.E. Counts, and E.J. Mufson Single Cell gene expression profiling in Alzheimer's disease Neurorx 3 2006 302 318
4. L. Bertram, R. Busch, M. Spiegl, N.T. Lautenschlager, U. Muller, and A. Kurz Paternal age is a risk factor for Alzheimer disease in the absence of a major gene Neurogenetics 1 1998 277 280
5. M.S. Tsai, E.G. Tangalos, R.C. Petersen, G.E. Smith, D.J. Schaid, E. Kokmen, R.J. Ivnik, and S.N. Thibodeau Apolipoprotein-E - Risk factor for Alzheimer-disease Am. J. Hum. Genet. 54 1994 643 649
6. S. Fleminger Head injury as a risk factor for Alzheimer's disease J. Neurol. Neurosurg. Psychiatry 74 2003 832
7. I.J. Martins, E. Hone, J.K. Foster, S.I. Sunram-Lea, A. Gnjec, S.J. Fuller, D. Nolan, S.E. Gandy, and R.N. Martins Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease Mol. Psychiatry 11 2006 721 736
8. M. Kivipelto, M.P. Laakso, J. Tuomilehto, A. Nissinen, and H. Soininen Hypertension and hypercholesterolaemia as risk factors for Alzheimer's disease - Potential for pharmacological intervention CNS Drugs 16 2002 435 444
9. M. Kivipelto, and A. Solomon Cholesterol as a risk factor for Alzheimer's disease - epidemiological evidence Acta. Neurol. Scand. 114 2006 50 57
10. J.C. De la Torre How do heart disease and stroke become risk factors for Alzheimer's disease Neurol. Res. 28 2006 637 644
11. K.J. Anstey, C. von Sanden, A. Salim, and R. O'Kearney Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies Am. J. Epidemiol. 166 2007 367 378
12. I. Mebane-Sims 2009 Alzheimer's disease facts and figures Alzheimers Demen. 5 2009 234 270
13. R. Schmidt, E. Assem-Hilger, T. Benke, P. Dal-Bianco, M. Delazer, G. Ladurner, K. Jellinger, J. Marksteiner, G. Ransmayr, H. Schmidt, E. Stogmann, J. Wancata, and C. Wehringer Sex differences in Alzheimer disease Neuropsychiatrie 22 2008 1 15
14. L.E. Hebert, P.A. Scherr, J.J. McCann, L.A. Beckett, and D.A. Evans Is the risk of developing Alzheimer's disease greater for women than for men? Am. J. Epidemiol. 153 2001 132 136
15. M.B. Patwardhan, D.C. McCrory, D.B. Matchar, G.P. Samsa, and O.T. Rutschmann Alzheimer disease: operating characteristics of PET- A meta-Analysis Radiology 273 2004 73 80
16. R.C. Mohs The clinical syndrome of Alzheimer's disease: aspects particularly relevant to clinical trials Genes Brain Behav. 4 2005 129 133
17. R. Brookmeyer, E. Johnson, K. Ziegler-Graham, and H.M. Arrighi Forecasting the global burden of Alzheimer's disease Alzheimer's Demen. 3 2007 186 191
18. E. Scarpini, P. Scheltens, and H. Feldman Treatment of Alzheimer's disease: current status and new perspectives Lancet Neurol. 2 2003 539 547
19. R.T. Bartus, R.L. Dean, B. Beer, and A.S. Lippa The cholinergic hypothesis of Geriatric memory Dysfunction Science 217 1982 408 417
20. P.T. Francis, A.M. Palmer, M. Snape, and G.K. Wilcock The cholinergic hypothesis of Alzheimer's disease: a review of progress J. Neurol. Neurosurg. Psychiatry 66 1999 137 147
21. J.L. Cummings, and D. Kaufer Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited Neurology 47 1996 876 883
22. E.K. Perry The cholinergic hypothesis - 10 Years on Br. Med. Bull. 42 1986 63 69
23. A. Lleo, S.M. Greenberg, and J.H. Growdon Current pharmacotherapy for Alzheimer's disease Annu. Rev. Med. 57 2006 513 533
24. Alzheimer's disease: FDA's role in new product development www.fda.gov/NewsEvents/Testimony/ucm110879.htm (Access date May 2010)
25. M.R. Farlow, and J.L. Cummings Effective pharmacologic management of Alzheimer's disease Am. J. Med. 120 2007 388 397
26. J.L. Cummings Cholinesterase inhibitors: a new class of psychotropic compounds Am. J. Psychiatry 157 2000 4 15
27. S.L. Rogers, M.R. Farlow, R.S. Doody, R. Mohs, L.T. Friedhoff, B. Albala, B. Baumel, G. Booker, J. Dexter, M. Farmer, J.P. Feighner, S. Ferris, B. Gordon, D.G. Gorman, G. Hanna, L.E. Harrell, R. Hubbard, J. Kennedy, J. McCarthy, D.W. Scharre, F. Schaerf, L. Schneider, B. Seltzer, A. Siegal, S.R. Stark, A. Strauss, and T.M. Walshe A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease Neurology 50 1998 136 145
28. P.N. Tariot, P.R. Solomon, J.C. Morris, P. Kershaw, S. Lilienfeld, and C. Ding A 5-month, randomized, placebo-controlled trial of galantamine in AD Neurology 54 2000 2269 2276
29. M.A. Findeis The role of amyloid beta peptide 42 in Alzheimer's disease Pharmacol. Ther. 116 2007 266 286
30. L.L. Shen, G.X. Liu, and Y. Tang Molecular docking and 3D-QSAR studies of 2-substituted 1-indanone derivatives as acetylcholinesterase inhibitors Acta. Pharmacol. Sin 28 2007 2053 2063
31. J. Marco-Contelles, M.D. Carreiras, C. Rodriguez, M. Villarroya, and A.G. Garcia Synthesis and pharmacology of galantamine Chem. Rev. 106 2006 116 133
32. H. Sugimoto, Y. Yamanishi, Y. Iimura, and Y. Kawakami Donepezil hydrochloride (E2020) and other acetylcholinesterase inhibitors Curr. Med. Chem. 7 2000 303 339
33. Y.C. Xu, J.P. Colletier, M. Weik, H.L. Jiang, J. Moult, I. Silman, and J.L. Sussman Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics Biophys. J. 95 2008 2500 2511
34. G. Kryger, I. Silman, and J.L. Sussman Three-dimensional structure of a complex of E2020 with acetylcholinesterase from Torpedo californica J. Physiol. Paris 92 1998 191 194
35. A. Villalobos, J.F. Blake, C.K. Biggers, T.W. Butler, D.S. Chapin, Y.P.L. Chen, J.L. Ives, S.B. Jones, D.R. Liston, A.A. Nagel, D.M. Nason, J.A. Nielsen, I.A. Shalaby, and W.F. White Novel Benzisoxazole derivatives as potent and selective inhibitors of acetylcholinesterase J. Med. Chem. 37 1994 2721 2734
36. A.A. Nagel, D.R. Liston, S. Jung, M. Mahar, L.A. Vincent, D. Chapin, Y.L. Chen, S. Hubbard, J.L. Ives, S.B. Jones, J.A. Nielsen, A. Ramirez, I.A. Shalaby, A. Villalobos, and W.F. White Design and synthesis of l-Heteroaryl-3-(1-benzyl-4-piperidinyl)propan-1-one derivatives as potent, selective acetylcholinesterase inhibitors J. Med. Chem. 38 1995 1084 1089
37. Y. Ishichi, M. Sasaki, M. Setoh, T. Tsukamoto, S. Miwatashi, H. Nagabukuro, S. Okanishi, S. Imai, R. Saikawa, T. Doi, and Y. Ishihara Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}-1,2,5,6- tetrahydro-4H- pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds Bioorg. Med. Chem. 13 2005 1901 1911
38. A. Villalobos, T.W. Butler, D.S. Chapin, Y.L. Chen, S.B. Demattos, J.L. Ives, S.B. Jones, D.R. Listen, A.A. Nagel, D.M. Nason, J.A. Nielsen, A.D. Ramirez, I.A. Shalaby, and W.F. White 5,7-Dihydro-3-[2-[1-(phenylmethyl)-4- piperidinyl]ethyl]6- H-pyrrolo[3,2- f]-1,2-benzisoxazol-6-one: a potent and Centrally-selective inhibitor of acetylcholinesterase with an Improved Margin of Safety J. Med. Chem. 38 1995 2802 2808
39. G.L. Ellman, K.D. Courtney, V. Andres, R.M. Featherstone, New, and Rapid Colorimetric Determination of acetylcholinesterase activity Biochem. Pharmacol. 7 1961 88
40. H. Kubinyi Hansch Analysis and Related Approaches 1993 VCH New York
41. Spartan 06 2006 Wavefunction, Inc 18401 Von Karman Avenue, Suite 370 Irvine, CA 92612, USA
42. ®): implications for the design of new anti-Alzheimer drugs Structure 7 1999 297 307
43. M.J.S. Dewar, E.G. Zoebisch, E.F. Healy, and J.J.P. Stewart Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model J. Am. Chem. Soc. 107 1985 3902 3909
44. G. Kryger, M. Harel, K. Giles, L. Toker, B. Velan, A. Lazar, C. Kronman, D. Barak, N. Ariel, A. Shafferman, I. Silman, and J.L. Sussman Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II Acta Crystallogr. Sect. D: Biol. Crystallogr. 56 2000 1385 1394
45. A. Sali, and T.L. Blundell Comparative protein modeling by satisfaction of spatial restraints J. Mol. Biol. 234 1993 779 815
46. C. Notredame, D.G. Higgins, and J. Heringa T-Coffee: a novel method for fast and accurate multiple sequence alignment J. Mol. Biol. 302 2000 205 217
47. G.N. Ramachandran, and V. Sasisekharan Conformation of Polypeptides and Proteins Adv. Protein Chem. 23 1968 283 437
48. R.A. Laskowski, M.W. Macarthur, D.S. Moss, and J.M. Thornton Procheck - A program to Check the Stereochemical quality of protein structures J. Appl. Crystallogr. 26 1993 283 291
49. Sybyl V.8.0 2008 Tripos Inc 1699 S. Hanley Rd., St. Louis, MO, USA
50. B. Hess, C. Kutzner, D. van der Spoel, and E. Lindahl GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation J. Chem. Theory Comput. 4 2008 435 447
51. W.F. van Gunsteren, S.R. Billeter, A.A. Eising, P.H. Hünenberger, P. Krüger, A.E. Mark, W.R.P. Scott, and I.G. Tironi Biomolecular Simulation: The GROMOS96 Manual and User Guide, VdF: Hochschulverlag AG an der ETH Zürich and BIOMOS b.v 1996 Zürich Groningen
52. D.M.F. vanAalten, R. Bywater, J.B.C. Findlay, M. Hendlich, R.W.W. Hooft, and G. Vriend PRODRG, a program for generating molecular topologies and unique molecular descriptors from coordinates of small molecules J. Comput-Aided. Mol. Des 10 1996 255 262
53. H.J.C. Berendsen, J.P.M. Postma, W.F. Vangunsteren, A. Dinola, and J.R. Haak Molecular-dynamics with coupling to an external bath J. Chem. Phys. 81 1984 3684 3690
54. B. Hess, H. Bekker, H.J.C. Berendsen, and J. Fraaije LINCS: a linear constraint solver for molecular simulations J. Comput. Chem. 18 1997 1463 1472
55. L. Verlet Computer experiments on Classical Fluids. I. Thermodynamical Properties of Lennard-Jones molecules Phys. Rev. 159 1967 98 103
56. T. Darden, D. York, and L. Pedersen Particle Mesh Ewald - an N.Log(N) method for Ewald sums in large Systems J. Chem. Phys. 98 1993 10089 10092
57. A.J. Hopfinger, S. Wang, J.S. Tokarski, B.Q. Jin, M. Albuquerque, P.J. Madhav, and C. Duraiswami Construction of 3D-QSAR models using the 4D-QSAR analysis formalism J. Am. Chem. Soc. 119 1997 10509 10524
58. N.C. Romeiro, M.G. Albuquerque, R.B. de Alencastro, M. Ravi, and A.J. Hopfinger Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors J. Mol. Model. 12 2006 855 868
59. D. Rogers, and A.J. Hopfinger Application of genetic function approximation to quantitative structure-activity-relationships and quantitative structure-property relationships J. Chem. Inf. Comput. Sci. 34 1994 854 866
60. W.G. Glen, W.J. Dunn, and D.R. Scott Principal components analysis and partial least squares regression Tetrahedron Comput. Methodol. 2 1989 349 376
61. H. Kubinyi QSAR and 3D QSAR in drug design. 1. methodology Drug Discov. Today 2 1997 457 467
62. D. Rogers Some Theory and examples of genetic function approximation with comparison to Evolutionary techniques D. James, Genetic Algorithms in Molecular Modeling 1996 Academic Press London 87 107
63. D. Livingstone Data Analysis for Chemists 1995 Oxford University Press New York
64. D. Jaiswal, C. Karthikeyan, and P. Trivedi Rationalization of Physicochemical Properties of Alkanoic acid derivatives towards Histone Deacetylase inhibition Internet Electron. J. Mol. Des. 5 2006 13 26
65. J.K. Clark, P. Cowley, A.W. Muir, R. Palin, E. Pow, A.B. Prosser, R. Taylor, and M.Q. Zhang Quaternary salts of E2020 analogues as acetylcholinesterase inhibitors for the reversal of neuromuscular block Bioorg. Med. Chem. Lett. 12 2002 2565 2568 (Pubitemid 35245282)
66. K. Matsui, Y. Oda, H. Ohe, S. Tanaka, and N. Asakawa Direct determination of E2020 enantiomers in plasma by liquid-chromatography mass-spectrometry and column-switching techniques J. Chromatogr. A 694 1995 209 218
67. Molinspiration property calculation Service http://www.molinspiration. com/ (Access date April 2010)
68. Thomas Sander Osiris Property Explorer http://www.organic-chemistry.org/ prog/peo/ (Access date April 2010)